yttrium Y 90 tabituximab barzuxetan

{
  "id": "MLC-T-ONC-017638",
  "term": "yttrium Y 90 tabituximab barzuxetan",
  "field": "Oncology and biomedicine",
  "definition": "A radioimmunoconjugate composed of a humanized monoclonal antibody (MoAb) tabituximab barzuxetan against FZD10 and labeled with yttrium Y 90, with potential antineoplastic activity. The MoAb moiety of yttrium Y 90 tabituximab barzuxetan binds to FZD10, thereby delivering a cytotoxic dose of beta radiation to FZD10 positive tumor cells. FZD10 (also called CD350), a member of the Frizzled family of G protein-coupled receptors that is involved in the Wnt/beta-catenin/TCF signaling pathway, is overexpressed in a variety of cancer cell types but undetectable in normal, healthy human tissues except the placenta.",
  "abbreviation": "OTSA101-DTPA-90Y",
  "synonyms": [
    "90Y tabituximab barzuxetan",
    "yttrium Y 90-labeled anti-FZD10 monoclonal antibody OTSA101"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/yttrium-y-90-tabituximab-barzuxetan/"
}